325 related articles for article (PubMed ID: 2845409)
1. DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss J; Wang JC
Proc Natl Acad Sci U S A; 1988 Oct; 85(20):7501-5. PubMed ID: 2845409
[TBL] [Abstract][Full Text] [Related]
2. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Robinson MJ; Osheroff N
Biochemistry; 1990 Mar; 29(10):2511-5. PubMed ID: 2159323
[TBL] [Abstract][Full Text] [Related]
4. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
[TBL] [Abstract][Full Text] [Related]
5. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng WK; Faucette L; Johnson RK; Sternglanz R
Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
[TBL] [Abstract][Full Text] [Related]
6. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.
Bjornsti MA; Benedetti P; Viglianti GA; Wang JC
Cancer Res; 1989 Nov; 49(22):6318-23. PubMed ID: 2553253
[TBL] [Abstract][Full Text] [Related]
7. Using yeast to understand drugs that target topoisomerases.
Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J
Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498
[No Abstract] [Full Text] [Related]
8. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
van Hille B; Clerc X; Creighton AM; Hill BT
Br J Cancer; 1999 Nov; 81(5):800-7. PubMed ID: 10555749
[TBL] [Abstract][Full Text] [Related]
9. Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.
Woo MH; Vance JR; Bjornsti MA
Methods Mol Biol; 2001; 95():303-13. PubMed ID: 11089242
[No Abstract] [Full Text] [Related]
10. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons.
Knab AM; Fertala J; Bjornsti MA
J Biol Chem; 1995 Mar; 270(11):6141-8. PubMed ID: 7890748
[TBL] [Abstract][Full Text] [Related]
11. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage.
Vance JR; Wilson TE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13669-74. PubMed ID: 12368472
[TBL] [Abstract][Full Text] [Related]
12. Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae.
Sloan R; Huang SN; Pommier Y; Jinks-Robertson S
DNA Repair (Amst); 2017 Nov; 59():69-75. PubMed ID: 28961461
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation in DNA topoisomerase I of yeast causes DNA damage and RAD9-dependent cell cycle arrest.
Levin NA; Bjornsti MA; Fink GR
Genetics; 1993 Apr; 133(4):799-814. PubMed ID: 8385050
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Nitiss JL; Wang JC
Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
[TBL] [Abstract][Full Text] [Related]
16. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
Lin JH; Castora FJ
Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
[TBL] [Abstract][Full Text] [Related]
17. Human topoisomerase I mediates illegitimate recombination leading to DNA insertion into the ribosomal DNA locus in Saccharomyces cerevisiae.
Zhu J; Schiestl RH
Mol Genet Genomics; 2004 Apr; 271(3):347-58. PubMed ID: 15007730
[TBL] [Abstract][Full Text] [Related]
18. Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.
Bjornsti MA; Knab AM; Benedetti P
Cancer Chemother Pharmacol; 1994; 34 Suppl():S1-5. PubMed ID: 8070016
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.
van Waardenburg RC; de Jong LA; van Delft F; van Eijndhoven MA; Bohlander M; Bjornsti MA; Brouwer J; Schellens JH
Mol Cancer Ther; 2004 Apr; 3(4):393-402. PubMed ID: 15078982
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants.
Knab AM; Fertala J; Bjornsti MA
J Biol Chem; 1993 Oct; 268(30):22322-30. PubMed ID: 8226741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
